Lifecore Biomedical, Inc. De (LFCR) Liabilities and Shareholders Equity (2011 - 2025)

Lifecore Biomedical's Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $239.3 million for Q2 2025.

• In Q2 2025, Liabilities and Shareholders Equity fell 5.76% year-over-year to $239.3 million; the TTM figure through May 2025 stood at $979.2 million (down 1.25% YoY), while the FY2025 annual figure was $239.3 million, down 5.76% from the prior year.
• Liabilities and Shareholders Equity was $239.3 million for Q2 2025 at Lifecore Biomedical, up from $237.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $506.9 million in Q1 2021 to a low of $236.7 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $304.3 million across 5 years, with a median of $254.7 million in 2024.
• The sharpest annual moves came in 2021 and 2022: Liabilities and Shareholders Equity jumped 71.0% in 2021, then slumped 45.27% in 2022.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $421.3 million in 2021, then plunged by 34.5% to $276.0 million in 2022, then decreased by 10.93% to $245.8 million in 2023, then advanced by 3.89% to $255.4 million in 2024, then retreated by 6.28% to $239.3 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $239.3 million (Q2 2025), $237.7 million (Q1 2025), and $255.4 million (Q4 2024), per Business Quant data.